Platelet-tolymphocyte ratio in patients with metastatic breast cancer treated with eribulin

被引：0
|
作者：
Shimada, Hiroko
Matsuura, Kazuo
Kohyama, Shunsuke
Asano, Aya
Ohara, Masahiro
Ishiguro, Hiroshi
Osaki, Akihiko
Saeki, Toshiaki
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO2-15-03
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO2-15-03
引用
收藏
页数：2
相关论文
共 50 条
  • [41] The Place for Eribulin in the Treatment of Metastatic Breast Cancer
    Gradishar, William J.
    CURRENT ONCOLOGY REPORTS, 2011, 13 (01) : 11 - 16
  • [42] Eribulin in Recurrent/Metastatic Breast Cancer (MBC)
    Taha Sethjiwala
    Manikandan Dhanushkodi
    Venkatraman Radhakrishnan
    Jayachandran Perumal Kalaiarasi
    Nikita Mehra
    Archit Joshi
    Arun Kumar Rajan
    Gangothri Selvarajan
    Balasubramanian Ananthi
    Priya Iyer
    Geetha Senguttuvan
    Bharathi Srilatha
    Arvind Krishnamurthy
    Sridevi Velusamy
    Selvaluxmy Ganesarajah
    Trivadi S. Ganesan
    Tenali Gnana Sagar
    Indian Journal of Gynecologic Oncology, 2019, 17
  • [43] Eribulin in Recurrent/Metastatic Breast Cancer (MBC)
    Sethjiwala, Taha
    Dhanushkodi, Manikandan
    Radhakrishnan, Venkatraman
    Kalaiarasi, Jayachandran Perumal
    Mehra, Nikita
    Joshi, Archit
    Rajan, Arun Kumar
    Selvarajan, Gangothri
    Ananthi, Balasubramanian
    Iyer, Priya
    Senguttuvan, Geetha
    Srilatha, Bharathi
    Krishnamurthy, Arvind
    Velusamy, Sridevi
    Ganesarajah, Selvaluxmy
    Ganesan, Trivadi S.
    Sagar, Tenali Gnana
    INDIAN JOURNAL OF GYNECOLOGIC ONCOLOGY, 2019, 17 (03)
  • [44] The safety of eribulin for the treatment of metastatic breast cancer
    Manuel Perez-Garcia, Jose
    Cortes, Javier
    EXPERT OPINION ON DRUG SAFETY, 2019, 18 (05) : 347 - 355
  • [45] High ALC, low NLR and PLR are associated with longer OS in patients with metastatic breast cancer treated with eribulin
    Matsuura, Kazuo
    Osaki, Akihiko
    Nakame, Ayako
    Fujimoto, Akihiro
    Ichinose, Yuki
    Nukui, Asami
    Asano, Aya
    Shimada, Hiroko
    Sano, Hiroshi
    Kosaka, Yoshimasa
    Hasebe, Takahiro
    Sakakibara, Ayaka
    Saeki, Toshiaki
    ANNALS OF ONCOLOGY, 2021, 32 : S319 - S319
  • [46] Is eribulin treatment prognostic factor in patients with metastatic breast cancer treated with this drug? Retrospective analysis of a multicentre study
    Oruc, Zeynep
    Kaplan, Muhammet Ali
    Geredeli, Caglayan
    Sari, Nilgun Yildirim
    Ozaslan, Ersin
    Aytekin, Aydin
    Elkiran, Emin Tamer
    Koca, Sinan
    Dogan, Mutlu
    Turan, Nedim
    Yuce, Ozlem
    Sevinc, Alper
    Ercelep, Ozlem
    Isikdogan, Abdurrahman
    JOURNAL OF BUON, 2020, 25 (02): : 641 - 647
  • [47] Population Pharmacometric Analyses of Eribulin in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
    Majid, Oneeb
    Gupta, Anubha
    Reyderman, Larisa
    Olivo, Martin
    Hussein, Ziad
    JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 54 (10): : 1134 - 1143
  • [48] Is eribulin treatment prognostic factor in patients with metastatic breast cancer treated with this drug? Retrospective analysis of a multicentre study
    Oruc, Zeynep
    Kaplan, Muhammet Ali
    Geredeli, Caglayan
    Sari, Nilgun Yildirim
    Ozaslan, Ersin
    Aytekin, Aydin
    Elkiran, Emin Tamer
    Koca, Sinan
    Dogan, Mutlu
    Turan, Nedim
    Yuce, Ozlem
    Sevinc, Alper
    Ercelep, Ozlem
    Isikdogan, Abdurrahman
    JOURNAL OF BUON, 2019, 24 (05): : 1876 - 1883
  • [49] Efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with anthracycline/taxanes
    Chen, Lan
    Yan, Xi
    Luo, Ting
    Tian, Tinglun
    He, Ping
    Zhong, Xiaorong
    CANCER MEDICINE, 2024, 13 (10):
  • [50] Association of clinicopathological parameters with outcome in patients with metastatic breast cancer treated with eribulin in South East London.
    Li, Su
    Agorastos, Antonios
    Kristeleit, Hartmut
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345